Animal data in hand, Nessan Bermingham banks $91.5M for Atlas-backed RNA editing play
Korro Bio, the RNA editing startup that got started on $4 million in seed funding from Atlas and some more cash from New Enterprise Associates, has brought in $91.5 million for its Series A haul.
Under executive chairman Nessan Bermingham, the biotech has racked up animal data that he said show “pretty high targeted editing straight out of the gate.” Off-target activity wasn’t an issue, and the OPERA platform appeared able to zero in on multiple types of RNA.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.